Entera Bio Rebounds As Investors Balance Phase 3 Funding Against Dilution Riskbenzinga_article·8 hours agoENTX-7.98%
Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE | ENTX Stock NewsStockTitan·13 hours agoENTX-7.98%
Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquiredrttnews·1 day ago, 10:34 PMFBRX-0.16%TVGNW-9.35%
OPK: Q2 2026 revenue rose and losses narrowed, with clinical and partnership progress highlightedQuartr·2 days ago, 03:11 PMOPK-17.27%ENTX-7.98%
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga_article·2 days ago, 12:06 PMMPLT+22.01%PFSA-4.71%
Entera Bio surges 89% on $275M private placement for EB613 trialUS Stock Market Update·2 days ago, 12:00 PMENTX-7.98%
Entera Bio surges 51% on $275M private placement to fund Phase 3US Stock Market Update·2 days ago, 08:51 AMENTX-7.98%
Entera Bio prices USD 275 million private placement at USD 2.04 per sharePUBT·2 days ago, 07:32 AMENTX-7.98%
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga_article·Jul 16 at 07:05 AMATAI0.00%DCOY-0.25%
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga_article·Jun 22 at 07:05 AMCRVO-3.13%CDT-13.27%
Entera Bio shares are trading higher after the company announced the FDA accepted its plan to conduct a single, randomized, double-blind, placebo-controlled, Phase 3 trial to support a potential New Drug Application submission for EB613.benzinga_article·Jun 22 at 11:34 AMENTX-7.98%
